Budesonide promotes airway epithelial barrier integrity following double-stranded RNA challenge.

Airway epithelial barrier dysfunction is increasingly recognized as a key feature of asthma and other lung diseases. Respiratory viruses are responsible for a large fraction of asthma exacerbations, and are particularly potent at disrupting epithelial barrier function through pattern recognition rec...

Full description

Saved in:
Bibliographic Details
Main Authors: Clara Rimmer, Savas Hetelekides, Sophia I Eliseeva, Steve N Georas, Janelle M Veazey
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2021-01-01
Series:PLoS ONE
Online Access:https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0260706&type=printable
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850043007863095296
author Clara Rimmer
Savas Hetelekides
Sophia I Eliseeva
Steve N Georas
Janelle M Veazey
author_facet Clara Rimmer
Savas Hetelekides
Sophia I Eliseeva
Steve N Georas
Janelle M Veazey
author_sort Clara Rimmer
collection DOAJ
description Airway epithelial barrier dysfunction is increasingly recognized as a key feature of asthma and other lung diseases. Respiratory viruses are responsible for a large fraction of asthma exacerbations, and are particularly potent at disrupting epithelial barrier function through pattern recognition receptor engagement leading to tight junction dysfunction. Although different mechanisms of barrier dysfunction have been described, relatively little is known about whether barrier integrity can be promoted to limit disease. Here, we tested three classes of drugs commonly prescribed to treat asthma for their ability to promote barrier function using a cell culture model of virus-induced airway epithelial barrier disruption. Specifically, we studied the corticosteroid budesonide, the long acting beta-agonist formoterol, and the leukotriene receptor antagonist montelukast for their ability to promote barrier integrity of a monolayer of human bronchial epithelial cells (16HBE) before exposure to the viral mimetic double-stranded RNA. Of the three, only budesonide treatment limited transepithelial electrical resistance and small molecule permeability (4 kDa FITC-dextran flux). Next, we used a mouse model of acute dsRNA challenge that induces transient epithelial barrier disruption in vivo, and studied the effects budesonide when administered prophylactically or therapeutically. We found that budesonide similarly protected against dsRNA-induced airway barrier disruption in the lung, independently of its effects on airway inflammation. Taken together, these data suggest that an under-appreciated effect of inhaled budesonide is to maintain or promote airway epithelial barrier integrity during respiratory viral infections.
format Article
id doaj-art-bc61358d5fff4a3bb9ddde88fd61e9e9
institution DOAJ
issn 1932-6203
language English
publishDate 2021-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj-art-bc61358d5fff4a3bb9ddde88fd61e9e92025-08-20T02:55:20ZengPublic Library of Science (PLoS)PLoS ONE1932-62032021-01-011612e026070610.1371/journal.pone.0260706Budesonide promotes airway epithelial barrier integrity following double-stranded RNA challenge.Clara RimmerSavas HetelekidesSophia I EliseevaSteve N GeorasJanelle M VeazeyAirway epithelial barrier dysfunction is increasingly recognized as a key feature of asthma and other lung diseases. Respiratory viruses are responsible for a large fraction of asthma exacerbations, and are particularly potent at disrupting epithelial barrier function through pattern recognition receptor engagement leading to tight junction dysfunction. Although different mechanisms of barrier dysfunction have been described, relatively little is known about whether barrier integrity can be promoted to limit disease. Here, we tested three classes of drugs commonly prescribed to treat asthma for their ability to promote barrier function using a cell culture model of virus-induced airway epithelial barrier disruption. Specifically, we studied the corticosteroid budesonide, the long acting beta-agonist formoterol, and the leukotriene receptor antagonist montelukast for their ability to promote barrier integrity of a monolayer of human bronchial epithelial cells (16HBE) before exposure to the viral mimetic double-stranded RNA. Of the three, only budesonide treatment limited transepithelial electrical resistance and small molecule permeability (4 kDa FITC-dextran flux). Next, we used a mouse model of acute dsRNA challenge that induces transient epithelial barrier disruption in vivo, and studied the effects budesonide when administered prophylactically or therapeutically. We found that budesonide similarly protected against dsRNA-induced airway barrier disruption in the lung, independently of its effects on airway inflammation. Taken together, these data suggest that an under-appreciated effect of inhaled budesonide is to maintain or promote airway epithelial barrier integrity during respiratory viral infections.https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0260706&type=printable
spellingShingle Clara Rimmer
Savas Hetelekides
Sophia I Eliseeva
Steve N Georas
Janelle M Veazey
Budesonide promotes airway epithelial barrier integrity following double-stranded RNA challenge.
PLoS ONE
title Budesonide promotes airway epithelial barrier integrity following double-stranded RNA challenge.
title_full Budesonide promotes airway epithelial barrier integrity following double-stranded RNA challenge.
title_fullStr Budesonide promotes airway epithelial barrier integrity following double-stranded RNA challenge.
title_full_unstemmed Budesonide promotes airway epithelial barrier integrity following double-stranded RNA challenge.
title_short Budesonide promotes airway epithelial barrier integrity following double-stranded RNA challenge.
title_sort budesonide promotes airway epithelial barrier integrity following double stranded rna challenge
url https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0260706&type=printable
work_keys_str_mv AT clararimmer budesonidepromotesairwayepithelialbarrierintegrityfollowingdoublestrandedrnachallenge
AT savashetelekides budesonidepromotesairwayepithelialbarrierintegrityfollowingdoublestrandedrnachallenge
AT sophiaieliseeva budesonidepromotesairwayepithelialbarrierintegrityfollowingdoublestrandedrnachallenge
AT stevengeoras budesonidepromotesairwayepithelialbarrierintegrityfollowingdoublestrandedrnachallenge
AT janellemveazey budesonidepromotesairwayepithelialbarrierintegrityfollowingdoublestrandedrnachallenge